ARK Genomic Revolution ETF (BATS:ARKG – Get Free Report)’s stock price hit a new 52-week high during trading on Monday. The stock traded as high as $55.35 and last traded at $55.4520, with a volume of 1455757 shares changing hands. The stock had previously closed at $54.00.
ARK Genomic Revolution ETF Stock Performance
The stock’s 50-day moving average price is $47.42 and its 200 day moving average price is $38.22.
Institutional Investors Weigh In On ARK Genomic Revolution ETF
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Midwest Financial Partners Investments Inc. grew its position in shares of ARK Genomic Revolution ETF by 2.1% during the 1st quarter. Midwest Financial Partners Investments Inc. now owns 209,416 shares of the company’s stock worth $5,533,000 after buying an additional 4,230 shares in the last quarter. Himension Capital Singapore PTE. LTD. bought a new stake in shares of ARK Genomic Revolution ETF in the first quarter valued at about $2,250,000. Baird Financial Group Inc. raised its holdings in shares of ARK Genomic Revolution ETF by 0.3% in the second quarter. Baird Financial Group Inc. now owns 73,722 shares of the company’s stock valued at $3,101,000 after acquiring an additional 255 shares in the last quarter. Client First Investment Management LLC purchased a new stake in ARK Genomic Revolution ETF in the second quarter worth about $2,579,000. Finally, Wealthfront Advisers LLC lifted its stake in ARK Genomic Revolution ETF by 4.9% in the first quarter. Wealthfront Advisers LLC now owns 54,391 shares of the company’s stock worth $1,437,000 after acquiring an additional 2,544 shares during the period.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
